PDF(Pubmed)
Abstract：
OBJECTIVE: The purpose of the study is to evaluate the visual outcomes and improvement in quality of life (QOL) of patients with keratoconus with scleral lenses.
METHODS: In this prospective study, 14 patients (28 eyes) with bilateral keratoconus were fitted with scleral lenses (McAsfeer 16.00 mm) in Pune city, Maharashtra, India. Uncorrected visual acuity (VA), best spectacle-corrected VA, and VA with scleral lenses were evaluated. The patients were given the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) for judging the QOL, before and after using scleral lenses for 3 months.
RESULTS: The mean uncorrected VA of the 14 patients with a mean age of 28.64 ± 6.57 years was 1.18 ± 0.19 logMAR. Best spectacle-corrected high-contrast VA improved from 0.47 ± 0.25 logMAR to 0.03 ± 0.07 logMAR with scleral lenses (P < 0.001). Best spectacle-corrected low-contrast VA improved from 0.68 ± 0.22 logMAR to 00.47 ± 0.10 logMAR with scleral lenses (P < 0.001). Along with the increase in overall median scores on the NEI VFQ-25 from 1735 to 2930 points (P < 0.001), the distance and near activities (P < 0.001), vision-specific mental health (P < 0.002), social functioning (P < 0.004), and driving (P < 0.005) improved after using scleral lenses for 3 months.
CONCLUSIONS: Scleral lenses can be an effective and safe management option for patients with keratoconus leading to an improved vision and QOL.
METHODS: In this prospective study, 14 patients (28 eyes) with bilateral keratoconus were fitted with scleral lenses (McAsfeer 16.00 mm) in Pune city, Maharashtra, India. Uncorrected visual acuity (VA), best spectacle-corrected VA, and VA with scleral lenses were evaluated. The patients were given the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) for judging the QOL, before and after using scleral lenses for 3 months.
RESULTS: The mean uncorrected VA of the 14 patients with a mean age of 28.64 ± 6.57 years was 1.18 ± 0.19 logMAR. Best spectacle-corrected high-contrast VA improved from 0.47 ± 0.25 logMAR to 0.03 ± 0.07 logMAR with scleral lenses (P < 0.001). Best spectacle-corrected low-contrast VA improved from 0.68 ± 0.22 logMAR to 00.47 ± 0.10 logMAR with scleral lenses (P < 0.001). Along with the increase in overall median scores on the NEI VFQ-25 from 1735 to 2930 points (P < 0.001), the distance and near activities (P < 0.001), vision-specific mental health (P < 0.002), social functioning (P < 0.004), and driving (P < 0.005) improved after using scleral lenses for 3 months.
CONCLUSIONS: Scleral lenses can be an effective and safe management option for patients with keratoconus leading to an improved vision and QOL.
摘要：
目的：该研究的目的是评估巩膜晶状体圆锥角膜患者的视觉结果和生活质量（QOL）的改善。
方法：在这项前瞻性研究中，在浦那市14例（28眼）双侧圆锥角膜患者安装巩膜晶状体（McAsfeer16.00mm），马哈拉施特拉邦,印度。未矫正视力（VA），最佳眼镜矫正VA，用巩膜晶状体和VA进行评估。患者接受美国国家眼科研究所视觉功能问卷-25（NEIVFQ-25）以判断QOL，前后使用巩膜晶状体3个月。
结果：14例平均年龄为28.64±6.57岁的患者的平均未校正VA为1.18±0.19logMAR。巩膜晶状体的最佳眼镜校正高对比度VA从0.47±0.25logMAR提高到0.03±0.07logMAR（P<0.001）。巩膜晶状体的最佳眼镜校正低对比度VA从0.68±0.22logMAR提高到00.47±0.10logMAR（P<0.001）。随着NEIVFQ-25的总体中位数分数从1735分增加到2930分（P<0.001），距离和近距离活动(P<0.001)，特定于视力的心理健康（P<0.002），社会功能（P<0.004），使用巩膜晶状体3个月后，驾驶（P<0.005）有所改善。
结论：巩膜晶状体可以是圆锥角膜患者的一种有效和安全的管理选择，从而改善视力和生活质量。
方法：在这项前瞻性研究中，在浦那市14例（28眼）双侧圆锥角膜患者安装巩膜晶状体（McAsfeer16.00mm），马哈拉施特拉邦,印度。未矫正视力（VA），最佳眼镜矫正VA，用巩膜晶状体和VA进行评估。患者接受美国国家眼科研究所视觉功能问卷-25（NEIVFQ-25）以判断QOL，前后使用巩膜晶状体3个月。
结果：14例平均年龄为28.64±6.57岁的患者的平均未校正VA为1.18±0.19logMAR。巩膜晶状体的最佳眼镜校正高对比度VA从0.47±0.25logMAR提高到0.03±0.07logMAR（P<0.001）。巩膜晶状体的最佳眼镜校正低对比度VA从0.68±0.22logMAR提高到00.47±0.10logMAR（P<0.001）。随着NEIVFQ-25的总体中位数分数从1735分增加到2930分（P<0.001），距离和近距离活动(P<0.001)，特定于视力的心理健康（P<0.002），社会功能（P<0.004），使用巩膜晶状体3个月后，驾驶（P<0.005）有所改善。
结论：巩膜晶状体可以是圆锥角膜患者的一种有效和安全的管理选择，从而改善视力和生活质量。
